211 related articles for article (PubMed ID: 18268929)
1. A dose-ranging study of tiotropium delivered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients.
Caillaud D; Le Merre C; Martinat Y; Aguilaniu B; Pavia D
Int J Chron Obstruct Pulmon Dis; 2007; 2(4):559-65. PubMed ID: 18268929
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients.
van Noord JA; Cornelissen PJ; Aumann JL; Platz J; Mueller A; Fogarty C
Respir Med; 2009 Jan; 103(1):22-9. PubMed ID: 19022642
[TBL] [Abstract][Full Text] [Related]
3. A randomized study of tiotropium Respimat Soft Mist inhaler vs. ipratropium pMDI in COPD.
Voshaar T; Lapidus R; Maleki-Yazdi R; Timmer W; Rubin E; Lowe L; Bateman E
Respir Med; 2008 Jan; 102(1):32-41. PubMed ID: 17996436
[TBL] [Abstract][Full Text] [Related]
4. Tiotropium 5microg via Respimat and 18microg via HandiHaler; efficacy and safety in Japanese COPD patients.
Ichinose M; Fujimoto T; Fukuchi Y
Respir Med; 2010 Feb; 104(2):228-36. PubMed ID: 19969446
[TBL] [Abstract][Full Text] [Related]
5. Effect of switching tiotropium HandiHaler® to Respimat® Soft Mist™ Inhaler in patients with COPD: the difference of adverse events and usability between inhaler devices.
Asakura Y; Nishimura N; Maezawa K; Terajima T; Kizu J; Chohnabayashi N
J Aerosol Med Pulm Drug Deliv; 2013 Feb; 26(1):41-5. PubMed ID: 22691112
[TBL] [Abstract][Full Text] [Related]
6. Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis.
Halpin DM; Dahl R; Hallmann C; Mueller A; Tashkin D
Int J Chron Obstruct Pulmon Dis; 2015; 10():239-59. PubMed ID: 25709423
[TBL] [Abstract][Full Text] [Related]
7. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.
Keam SJ; Keating GM
Treat Respir Med; 2004; 3(4):247-68. PubMed ID: 15350163
[TBL] [Abstract][Full Text] [Related]
8. A systematic review of comparative studies of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease: does inhaler choice matter?
Dahl R; Kaplan A
BMC Pulm Med; 2016 Oct; 16(1):135. PubMed ID: 27724909
[TBL] [Abstract][Full Text] [Related]
9. Tiotropium Respimat inhaler and the risk of death in COPD.
Wise RA; Anzueto A; Cotton D; Dahl R; Devins T; Disse B; Dusser D; Joseph E; Kattenbeck S; Koenen-Bergmann M; Pledger G; Calverley P;
N Engl J Med; 2013 Oct; 369(16):1491-501. PubMed ID: 23992515
[TBL] [Abstract][Full Text] [Related]
10. Comparative mortality risk of tiotropium administered via handihaler or respimat in COPD patients: are they equivalent?
Mathioudakis AG; Chatzimavridou-Grigoriadou V; Evangelopoulou E; Mathioudakis GA; Siafakas NM
Pulm Pharmacol Ther; 2014 Aug; 28(2):91-7. PubMed ID: 24846455
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the efficacy and safety of tiotropium bromide (5 µg) inhaled via Respimat in Chinese patients with chronic obstructive pulmonary disease.
Tang Y; Massey D; Zhong NS
Chin Med J (Engl); 2013; 126(19):3603-7. PubMed ID: 24112149
[TBL] [Abstract][Full Text] [Related]
12. The Tiotropium Safety and Performance in Respimat Trial (TIOSPIR), a large scale, randomized, controlled, parallel-group trial-design and rationale.
Wise RA; Anzueto A; Calverley P; Dahl R; Dusser D; Pledger G; Koenen-Bergmann M; Joseph E; Cotton D; Disse B
Respir Res; 2013 Apr; 14(1):40. PubMed ID: 23547660
[TBL] [Abstract][Full Text] [Related]
13. Tiotropium versus placebo for chronic obstructive pulmonary disease.
Karner C; Chong J; Poole P
Cochrane Database Syst Rev; 2012 Jul; (7):CD009285. PubMed ID: 22786525
[TBL] [Abstract][Full Text] [Related]
14. The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes.
Anzueto A; Wise R; Calverley P; Dusser D; Tang W; Metzdorf N; Dahl R
Respir Res; 2015 Sep; 16(1):107. PubMed ID: 26369563
[TBL] [Abstract][Full Text] [Related]
15. Tiotropium versus placebo for chronic obstructive pulmonary disease.
Karner C; Chong J; Poole P
Cochrane Database Syst Rev; 2014 Jul; 2014(7):CD009285. PubMed ID: 25046211
[TBL] [Abstract][Full Text] [Related]
16. Double-blind randomized parallel group study comparing the efficacy and safety of tiotropium and ipratropium in the treatment of COPD patients in Taiwan.
Hsu JY; Perng RP; Lu JY; Wu CP; Huang MS; Luh KT; Yang PC
J Formos Med Assoc; 2006 Sep; 105(9):708-14. PubMed ID: 16959618
[TBL] [Abstract][Full Text] [Related]
17. Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease.
Cheyne L; Irvin-Sellers MJ; White J
Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD009552. PubMed ID: 26391969
[TBL] [Abstract][Full Text] [Related]
18. Use of tiotropium Respimat Soft Mist Inhaler versus HandiHaler and mortality in patients with COPD.
Verhamme KM; Afonso A; Romio S; Stricker BC; Brusselle GG; Sturkenboom MC
Eur Respir J; 2013 Sep; 42(3):606-15. PubMed ID: 23520322
[TBL] [Abstract][Full Text] [Related]
19. Tiotropium Respimat(®) Versus HandiHaler(®): Comparison of Bronchodilator Efficacy of Various Doses in Clinical Trials.
Calverley PM; Könen-Bergmann M; Richard F; Bell S; Hohlfeld JM
Adv Ther; 2016 May; 33(5):786-93. PubMed ID: 27084728
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies.
Bateman E; Singh D; Smith D; Disse B; Towse L; Massey D; Blatchford J; Pavia D; Hodder R
Int J Chron Obstruct Pulmon Dis; 2010 Aug; 5():197-208. PubMed ID: 20714373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
